How to calculate pre-test probability for DVT and PE, when to use D-Dimer vs direct imaging, the CTPA and ultrasound pathways, and when to start anticoagulation before imaging.
A swollen leg. Unexplained breathlessness. A sudden sharp chest pain with a racing heart. These symptoms bring patients to doctors every day — and the critical diagnostic question is always: could this be a blood clot?
Venous thromboembolism (VTE) — which includes deep vein thrombosis (DVT) in the legs and pulmonary embolism (PE) in the lungs — is a major cause of preventable death worldwide. Missed PE is a leading cause of unexpected in-hospital death. But the symptoms of DVT and PE are non-specific and can mimic dozens of other conditions. Scanning every patient who comes in with a swollen leg or chest pain would overwhelm radiology departments and expose millions to unnecessary radiation.
The Wells Score solves this problem. Developed by Dr Philip Wells and colleagues, it calculates the pre-test probability of DVT or PE from clinical features alone — telling the clinician whether to go straight to imaging, or first check a D-Dimer blood test to safely rule out VTE without a scan.
Deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, most commonly in the calf, thigh, or pelvis. The leg becomes swollen, warm, red, and painful. The danger is that the clot can break off and travel through the bloodstream to the lungs.
Pulmonary embolism (PE) occurs when a clot (usually from a DVT) lodges in the pulmonary arteries, blocking blood flow to part of the lung. Symptoms include sudden breathlessness, pleuritic chest pain, haemoptysis (coughing blood), and in severe cases, haemodynamic collapse and cardiac arrest. Massive PE is immediately life-threatening.
DVT and PE are part of the same disease spectrum — collectively called venous thromboembolism (VTE). DVT is present in approximately 70% of patients diagnosed with PE.
Understanding VTE risk factors helps explain why the Wells Score includes elements like recent surgery and active cancer. Key risk factors include:
There are two separate Wells Scores — one for DVT and one for PE. They use different criteria and should not be confused.
| Clinical Feature | Points |
|---|---|
| Active cancer (treatment ongoing, within 6 months, or palliative) | +1 |
| Paralysis, paresis, or recent plaster immobilisation of lower extremity | +1 |
| Recently bedridden > 3 days OR major surgery within 12 weeks | +1 |
| Localised tenderness along the deep venous system | +1 |
| Entire leg swollen | +1 |
| Calf swelling > 3 cm compared to asymptomatic leg | +1 |
| Pitting oedema confined to symptomatic leg | +1 |
| Collateral superficial veins (non-varicose) | +1 |
| Previously documented DVT | +1 |
| Alternative diagnosis at least as likely as DVT | −2 |
Interpretation: Score < 2 = DVT Unlikely. Score ≥ 2 = DVT Likely.
⚠️ The −2 "alternative diagnosis" criterion is critical and often missed. If cellulitis, Baker's cyst rupture, muscle haematoma, or post-thrombotic syndrome is equally or more likely than DVT, subtract 2 points. This item requires clinical judgement and significantly changes management.
| Clinical Feature | Points |
|---|---|
| Clinical signs and symptoms of DVT (leg swelling, tenderness) | +3 |
| PE is the most likely diagnosis or equally likely | +3 |
| Heart rate > 100 bpm | +1.5 |
| Immobilisation ≥ 3 days or surgery in the previous 4 weeks | +1.5 |
| Previous DVT or PE | +1.5 |
| Haemoptysis (coughing blood) | +1 |
| Active malignancy (treatment within 6 months or palliative) | +1 |
Interpretation: Score ≤ 4 = PE Unlikely. Score > 4 = PE Likely.
D-Dimer is a fibrin degradation product — a substance produced when the body breaks down a blood clot. A negative D-Dimer in a low-probability patient has a very high negative predictive value — it effectively rules out VTE without any imaging. This is its primary clinical value.
However, D-Dimer is notoriously non-specific. It is elevated in dozens of conditions where clot formation and breakdown occurs:
A positive D-Dimer alone does not diagnose VTE — it only indicates the need for imaging. In high-probability patients (Wells score likely), D-Dimer adds no value and imaging should proceed directly.
In patients over 50, a fixed D-Dimer threshold of 500 ng/mL becomes less useful — D-Dimer rises with age even without VTE, leading to many false positives. The age-adjusted D-Dimer threshold improves specificity in older patients:
Age-adjusted threshold = Age × 10 ng/mL (for patients > 50 years)
For example, an 80-year-old patient would have an adjusted D-Dimer threshold of 800 ng/mL rather than the standard 500 ng/mL — safely excluding more elderly patients from unnecessary CT scans.
Patient: 55-year-old woman, 2 weeks post right knee replacement surgery. Presents with sudden onset breathlessness and right-sided pleuritic chest pain. Heart rate 114 bpm. No leg swelling. No prior VTE or malignancy. No haemoptysis.
Wells PE Score = 6.0 → PE Likely
Score > 4 = PE Likely. Do NOT send D-Dimer — proceed directly to CTPA. Start therapeutic anticoagulation (LMWH or DOAC) immediately while awaiting the scan unless there is a strong contraindication.
Once VTE is confirmed on imaging, anticoagulation is the cornerstone of treatment. Goals are to prevent clot extension, prevent PE (if DVT), prevent recurrence, and allow natural clot resolution.
Direct oral anticoagulants are now the preferred treatment for most patients with acute DVT or PE (NICE, ESC, ASH guidelines):
| Drug | Dosing (VTE Treatment) | Key Notes |
|---|---|---|
| Rivaroxaban (Xarelto) | 15 mg BD × 21 days, then 20 mg OD | No bridging LMWH needed. With food. |
| Apixaban (Eliquis) | 10 mg BD × 7 days, then 5 mg BD | No bridging needed. Most studied in cancer-VTE. |
| Dabigatran (Pradaxa) | 150 mg BD after 5–10 days LMWH | Requires LMWH bridge. Avoid CrCl < 30. |
| Clinical Scenario | Minimum Duration |
|---|---|
| Provoked DVT/PE (surgery, trauma, immobility) — major transient risk factor | 3 months |
| Unprovoked DVT/PE — first episode, low bleed risk | Minimum 3–6 months; extended treatment considered |
| Recurrent VTE | Long-term (indefinite anticoagulation) |
| Active cancer-associated VTE | Continue until cancer resolved or inactive |
| Antiphospholipid syndrome | Long-term (indefinite) |
🩸 Calculate Wells DVT and PE pre-test probability: RxMedCalc Wells Score Calculator →
This article is for educational purposes based on NICE and ESC guidelines. VTE diagnosis and management decisions must be made by a qualified physician with full clinical assessment of the individual patient.
Built by an MBBS, AFIH Certified Physician in Punjab, India | RxMedCalc.com